Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study

Shinotoh, H; Inoue, O; Hirayama, K; Aotsuka, A; Asahina, M; Suhara, T; Yamazaki, T; Tateno, Y
May 1993
Journal of Neurology, Neurosurgery & Psychiatry;May1993, Vol. 56 Issue 5, p467
Academic Journal
No abstract available.


Related Articles

  • Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders. Lie-Hang Shen; Mei-Hsiu Liao; Yu-Chin Tseng // Journal of Biomedicine & Biotechnology;2012, Vol. 2012, p1 

    Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To date, there are numerous positron emission tomography...

  • Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Booij, Jan; Tissingh, Gerrit; Winogrodzka, Ania; van Royen, Eric A. // European Journal of Nuclear Medicine;1999, Vol. 26 Issue 2, p171 

    Abstract. Parkinsonism is a feature of a number of neurodegenerative diseases, including Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. The results of post-mortem studies point to dysfunction of the dopaminergic neurotransmitter system in patients with...

  • Individual time course of pre- and postsynaptic PET imaging may improve differential diagnosis of Parkinson's disease and multiple system atrophy: a case report. Ishibashi, Kenji; Nishina, Hirofumi; Ishiwata, Kiichi; Ishii, Kenji // BMC Research Notes;9/30/2015, Vol. 8 Issue 1, p1 

    Background: Many in vivo studies have shown a difference in pre- and/or postsynaptic imaging between Parkinson's disease and multiple system atrophy; however, time course differences in pre- and postsynaptic imaging between Parkinson's disease and multiple system atrophy have not been rigorously...

  • Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease? Le, W-D.; Jankovic, J. // Drugs & Aging;2001, Vol. 18 Issue 6, p389 

    Dopamine receptor agonists are playing an increasingly important role in the treatment of not only patients with advanced Parkinson's disease and those with levodopa-induced motor fluctuations, but also in the early treatment of the disease. This shift has been largely due to the demonstrated...

  • Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Tatsch, Klaus // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 5, p711 

    Investigates the effectiveness of single-photon emission tomography (SPET) imaging of dopamine in Parkinson's disease. Comparison between SPET and positron emission tomography; Description of Parkinson's disease; Measures of presynaptic function; Instrumentation and data evaluation; Clinical...

  • Brain PET oral 4: in vivo pharmacology I—dopamine and norepinephrine.  // Journal of Cerebral Blood Flow & Metabolism;Oct2009 Supplement 1, Vol. 29, pS59 

    The article discusses several studies about dopamine and norepinephrine. J. D. Beaver and colleagues examined the affinity of propyl-hexahydro-naphth-oxazin (PHNO) for the receptors D2 and D3 with the independent method. Other studies discussed include a positron emission tomography study on the...

  • Positron Emission Tomographic Evidence of Similarity Between Obesity and Drug Addiction. Wang, Gene-Jack; Volkow, Nora D.; Thanos, Panayotis K.; Fowler, Joanna S. // Psychiatric Annals;Feb2003, Vol. 33 Issue 2, p104 

    The article discusses the similarity between obesity and drug addiction through positron emission tomography (PET). Obesity can be defined as a complex disease of appetite regulation and energy metabolism. It is controlled by genetics, psychology, diet and other factors. Genetically, dopamine...

  • Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Piccini, Paola; Brooks, David J.; Bj�rklund, Anders; Gunn, Roger N.; Grasby, Paul M.; Rimoldi, Ornella; Brundin, Patrik; Hagell, Peter; Rehncrona, Stig; Widner, H�kan; Lindvall, Olle // Nature Neuroscience;Dec99, Vol. 2 Issue 12, p1137 

    Synaptic dopamine release from embryonic nigral transplants has been monitored in the striatum of a patient with Parkinson's disease using [[sup 11]C]-raclopride positron emission tomography to measure dopamine D[sub 2] receptor occupancy by the endogenous transmitter. In this patient, who had...

  • Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors. Rinne, J. O.; Iivanainen, M.; Metsähonkala, L.; Vainionpää, L.; Pääkkönen, L.; Någren, K.; Helenius, H. // Journal of Neural Transmission;Jan2004, Vol. 111 Issue 1, p59 

    Summary. We investigated the integrity of striatal dopaminergic system in seven patients with dopa-responsive dystonia (DRD). Dopamine transporter function ([11C]CFT) and D1 ([11C]NNC 756) and D2 receptors ([11C]raclopride) were studied in same patients using positron emission tomography....

  • Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Nandhagopal, Ramachandiran; Kuramoto, Lisa; Schulzer, Michael; Mak, Edwin; Cragg, Jacqueline; McKenzie, Jess; McCormick, Siobhan; Ruth, Thomas J.; Sossi, Vesna; de la Fuente-Fernandez, Raul; Stoessl, A. Jon // Brain: A Journal of Neurology;Nov2011, Vol. 134 Issue 11, p3290 

    Parkinson's disease is a relentlessly progressive neurodegenerative disease. Breakdown of compensatory mechanisms influencing putaminal dopamine processing could contribute to the progressive motor symptoms. We studied a cohort of 78 subjects (at baseline) with sporadic Parkinson's disease and...


Read the Article


Sign out of this library

Other Topics